Disease or Syndrome

FDA Refuses to Release Detailed Data on Claimed COVID Vaccine-Linked Child Deaths in Near Term

4 hours ago talkbio0Tagged COVID19 (disease), Data Release, Death of child, Myocarditis, United States Food and Drug Administration, vaccine oversight, Vaccine Safety, Vaccines

FDA; COVID-19 vaccine; child deaths; myocarditis; vaccine safety; Vinay Prasad; data release; vaccine oversight

Capricor Therapeutics Reports Positive Phase 3 HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy, Planning FDA Resubmission

4 hours ago talkbio0Tagged Capricor Therapeutics, cardiac function preservation, Clinical Trials, deramiocel, HOPE-3 trial, Muscular Dystrophy, Duchenne, Phase 3 clinical trial, regulatory approval pathway, Rejection, United States Food and Drug Administration, upper limb function

Capricor Therapeutics; Deramiocel; Duchenne muscular dystrophy; HOPE-3 trial; Phase 3 clinical trial; FDA rejection; cardiac function preservation; upper limb function; clinical trial results; regulatory approval pathway

Recent Developments on Vinay Prasad’s Leaked FDA Memo, Alzheimer’s Disease Updates, and Next-Gen Obesity Drugs

8 hours ago talkbio0Tagged Alzheimer 's disease, Cessation of life, Child, COVID19 (disease), next-generation, Obesity, research, United States Food and Drug Administration, Vaccines, Vinay Prasad FDA memo

Vinay Prasad FDA memo; COVID-19 vaccine deaths children; FDA vaccine approval changes; Alzheimer’s disease research 2025; obesity drugs next generation; COVID-19 vaccine safety controversy; FDA vaccine policy overhaul

Alkeus Pharmaceuticals Appoints Carlos Quezada-Ruiz as Chief Medical Officer

1 day ago talkbio0Tagged Alkeus, Biological Factors, Carlos Quezada-Ruiz, Chief Medical Officer, Clinical Research, gildeuretinol, Ophthalmology specialty, Retinal Diseases, Stargardt's disease

Alkeus Pharmaceuticals; Carlos Quezada-Ruiz; Chief Medical Officer; Stargardt disease; gildeuretinol; retinal diseases; ophthalmology; clinical research; biopharmaceutical leadership

Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy

2 days ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, gene therapy, Gene Writing, Investments, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Regeneron; gene writing; TSRA-196; AATD; alpha-1 antitrypsin deficiency; gene therapy; partnership; investment

OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting

2 days ago talkbio0Tagged annual, Antibody-Drug Conjugates, Asymmetric Septal Hypertrophy, CD64-targeting ADC, Leukemia, Myelocytic, Acute, Leukemia, Myelomonocytic, Chronic, meeting, Monocytic leukemia, OncoPrecision, Resistance (Psychotherapeutic)

OncoPrecision; ONC001; CD64-targeting ADC; monocytic leukemia; acute myeloid leukemia; ASH Annual Meeting; antibody-drug conjugate; CMML; therapy resistance

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at CTAD Conference

2 days ago talkbio0Tagged access program, Alzheimer 's disease, Clinical Trials, Cognition Therapeutics, CTAD, Lewy bodies, Neurodegenerative Disorders, Phase 3 clinical trial, Presenile dementia, sigma-2 receptor, Zervimesine

Cognition Therapeutics; Zervimesine; CT1812; Phase 3 clinical trial; Alzheimer’s disease; Clinical Trials on Alzheimer’s Disease (CTAD); neurodegenerative diseases; sigma-2 receptor; dementia with Lewy bodies; expanded access program

Whitehawk Therapeutics Appoints Margaret Dugan as Chief Medical Officer

2 days ago talkbio0Tagged Chief Medical Officer, Chronic multifocal osteomyelitis, Clinical Trials, Dracen Pharmaceuticals, Drug Development, Margaret Dugan, Neoplasms, Novartis, Schrödinger, therapeutic autologous dendritic cells, Whitehawk Therapeutics

Whitehawk Therapeutics; Margaret Dugan; Chief Medical Officer; CMO; oncology; ADC; drug development; clinical trials; Novartis; Dracen Pharmaceuticals; Schrödinger

Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships

2 days ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, ARPA-H grant, CAR-T, Clinical Trials, Gene Writing, genome engineering, in vivo, Lipid Nanoparticles, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Gene Writing; in vivo CAR-T; ARPA-H grant; Regeneron partnership; TSRA-196; alpha-1 antitrypsin deficiency; Lipid Nanoparticles; in vivo genome engineering; clinical trials

FDA’s Vinay Prasad Links 10 Child Deaths to COVID-19 Vaccines, Calls for Stricter Review Guidelines

2 days ago talkbio0Tagged Biological Factors, COVID19 (disease), Death of child, Evaluation, Myocarditis, United States Food and Drug Administration, vaccine guidelines, vaccine regulation, Vaccine Safety, Vaccines, VAERS, Vinay Prasad

FDA; Vinay Prasad; COVID-19 vaccines; child deaths; myocarditis; vaccine safety; vaccine regulation; biologics evaluation; VAERS; stricter vaccine guidelines